<DOC>
	<DOCNO>NCT03033745</DOCNO>
	<brief_summary>This multicenter , open-label , parallel-arm , non-randomized study design evaluate safety tolerability high infusion parameter IgPro20 subject primary immunodeficiency ( PID ) . A total 45 subject ( include least 14 [ 30 % ] pediatric subject ≤ 17 year age least 9 [ 20 % ] obese subject body mass index [ BMI ] ≥30 kg/m2 ) confirm PID evaluate study . The study include three cohort 15 subject follow : ) Pump-Assisted Volume Cohort ( weekly infusion ) , volume per injection site 25 mL 50 mL , ii ) Pump Assisted Flow Rate Cohort ( weekly infusion ) , flow rate per injection site 25 mL/hour 100 mL/hour , iii ) Manual Push Flow Rate Cohort ( 5 7 infusion per week ) , flow rate per injection site 25 30 mL/hour 120 mL/hour ( equivalent approximately 0.5 mL/minute 2 mL/minute ) . Each cohort test 3 infusion parameter level ( 4 pump-assisted flow rate cohort ) , repeat least 4 time duration 12 week ( 16 week flow rate cohort ) . After fourth infusion level , subject may switch next infusion parameter level ( eg , 25 50 mL/h ) . During study , weekly dose remain unchanged ( prescribed treat physician , usually within 100-200 mg/kg per week range ) ; respective infusion parameter evaluation change .</brief_summary>
	<brief_title>Safety Tolerability Higher Infusion Parameters IgPro20 ( Hizentra ) Subjects With Primary Immunodeficiency ( PID )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>Male female stable dose IgPro20 ( Hizentra ) therapy . Women childbearing potential must use agree continue use medically approve contraception ( must discuss study doctor ) must negative pregnancy test screening . Subjects PID , namely diagnosis common variable immunodeficiency Xlinked agammaglobulinemia , define Pan American Group Immune Deficiency European Society Immune Deficiencies . With infusion parameter specify : PumpAssisted Flow Rate Cohort subject Experience pumpassisted infusion IgPro20 tolerate flow rate 25 mL/h per injection site least 1 month prior study entry . PumpAssisted Volume Cohort subject Total weekly IgPro20 dose ≥ 50 mL ( ≥ 10 g ) . Experience pumpassisted infusion IgPro20 tolerate volume 25 mL/injection site least 1 month prior study entry . Manual Push Flow Rate Cohort subject Experience frequent ( 57 time per week ) infusion IgPro20 tolerate flow rate approximately 0.5 mL/min ( equivalent 2530 mL/h ) per injection site least 1 month prior study entry . The dose ( volume ) per injection site exceed 25 mL . Ongoing serious bacterial infection time screen . Other significant medical condition could increase risk subject . Females pregnant , breast feeding , plan pregnancy course study . Participation study Investigational Medicinal Product ( IMP ) IgPro20 within three month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>